Here are the 8-K filings from AMERICA GREAT HEALTH (AAGH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow AAGH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AAGH filings page.
America Great Health (AAGH) reports interim results from a small, observational clinical study of its ion‑modified peptide products AX-3 and PPY-3 used as adjunctive therapy. The study at Zhejiang Kangjing Hospital in China followed 10 subjects from December 2024 through May 2026, including 8 with solid tumors, 1 with malignant lymphoma and 1 with bronchiectasis with hemoptysis.
The report describes symptom improvements in some patients and detailed changes in vital signs, blood counts, lipids and immune-cell markers. Two subjects with advanced malignancies and multiple-organ failure died within approximately one month and were withdrawn. The hospital concluded there were no significant treatment-related toxicities or adverse effects aside from discomfort swallowing large capsules. America Great Health emphasizes that this was a non-randomized, uncontrolled, preliminary observation, that concurrent therapies confound interpretation, and that the results do not establish safety or efficacy; further controlled clinical studies would be required.
America Great Health reported that its Chief Financial Officer, Quinn Chen, submitted his resignation, which the company accepted on June 2, 2025, to be effective June 30, 2025. The company states that Mr. Chen is leaving for personal reasons and that there were no disagreements with the company, including no issues related to its operations, policies, or accounting practices.
The Board plans to search for internal and external candidates to fill the CFO role. Until a successor is appointed, President and Chief Executive Officer Mike Wang will also serve as Chief Financial Officer, acting as the company’s principal financial and principal accounting officer.